Daniel L. Miller

Daniel L. Miller

Auto-generated profile, based on publicly available information

Daniel L. Miller

Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, Missouri

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 December 2024 in Journal of the American Society of Cytopathology
Verified
Journal Article
Closed access
SSSwati Satturwar
Swati Satturwar
MCMargaret Compton
Margaret Compton
DMDaniel Miller
Daniel Miller
AGAllison Goldberg
Allison Goldberg
CMCindy McGrath
Cindy McGrath
SMSwati Mehrotra
Swati Mehrotra

29 June 2020 in Cancer Cytopathology
Verified
Journal Article
Closed access
PDF file
DMDaniel Miller
Daniel Miller
CMC. Paul Morris
C. Paul Morris
ZMZahra Maleki
Zahra Maleki
MWMarissa White
Marissa White
ERErika F. Rodriguez
Erika F. Rodriguez

1 July 2020 in Journal of the American Society of Cytopathology
Verified
Journal Article
Closed access
DMDaniel L. Miller
Daniel L. Miller
LTLester D.R. Thompson
Lester D.R. Thompson
JBJustin A. Bishop
Justin A. Bishop
LRLisa M. Rooper
Lisa M. Rooper
SASyed Z. Ali
Syed Z. Ali

12 May 2020 in Journal of the American Society of Cytopathology
Verified
Journal Article
Closed access
DMDaniel L. Miller
Daniel L. Miller
Sinchita Roy-ChowdhuriSinchita Roy-Chowdhuri
Sinchita Roy-Chowdhuri
PIPeter Illei
Peter Illei
AJAaaron James
Aaaron James
RHRalph Hruban
Ralph Hruban
SASyed Z. Ali
Syed Z. Ali

1 March 2021 in Journal of the American Society of Cytopathology
Verified
Journal Article
Closed access
DMDaniel L. Miller
Daniel L. Miller
EREfrain A. Ribeiro
Efrain A. Ribeiro
SRSinchita Roy-Chowdhuri
Sinchita Roy-Chowdhuri
PIPeter B. Illei
Peter B. Illei
MSMomin T. Siddiqui
Momin T. Siddiqui
SASyed Z. Ali
Syed Z. Ali

30 May 2025 in Journal of the American Society of Cytopathology
Verified
Journal Article
Open access
CDChristopher Dilli
Christopher Dilli
WMWilliam Mi
William Mi
DMDaniel L. Miller
Daniel L. Miller
Thyroid nodules are common, but most are benign. Concerning nodules undergo fine-needle aspiration (FNA) and are classified using The Bethesda System. Nodules with atypia of undetermined significance (AUS) [Bethesda III] have management options including surveillance, repeat FNA, molecular testing, and surgical evaluation. While molecular testing can reduce unnecessary surgeries, it is costly. This retrospective study assessed the feasibility of repeat FNA as a cost-effective alternative. We conducted a multi-institutional retrospective study of AUS nodules from 5 hospitals between September 1, 2018, and March 1, 2024. Only initial FNA cases were included; pediatric cases and those lost to follow up were excluded. Nodules were stratified by initial diagnostic choice (repeat FNA, molecular testing, surgical intervention). Clinical and ultrasonography findings were reviewed to determine associations with malignancy rates. Costs were estimated based on Medicare reimbursement rates. We identified 2649 nodules that underwent FNA, with 199 interpreted as AUS. Of these, 131 met the criteria. Repeat FNA resulted in a benign diagnosis in 48.7% of cases and AUS in 35.9%. Costs were lowest for nodules undergoing repeat FNA. There was no significant difference in rates of surgical intervention or malignancy compared to molecular testing. American College of Radiology Thyroid Imaging Reporting and Data System categories were not associated with malignancy rates. Only echogenic foci were significantly associated with malignancy (P = 0.03). Repeat FNA resolved approximately 50% of cases, with no significant differences in malignancy or surgical intervention rates compared to molecular testing. Repeat FNA is the most cost-effective initial step for managing AUS nodules. Prebiopsy ultrasonography had limited utility in stratifying malignancy risk for AUS nodules.